Cargando…
Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand
BACKGROUND: Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients. We therefore conducted a retrospective study of 42 consecu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828404/ https://www.ncbi.nlm.nih.gov/pubmed/20051128 http://dx.doi.org/10.1186/1756-8722-3-1 |
_version_ | 1782178000330031104 |
---|---|
author | Niparuck, Pimjai Sorakhunpipitkul, Ladda Atichartakarn, Vichai Chuncharunee, Suporn Ungkanont, Artit Aungchaisuksiri, Pantep Puavilai, Teeraya Jootar, Saengsuree |
author_facet | Niparuck, Pimjai Sorakhunpipitkul, Ladda Atichartakarn, Vichai Chuncharunee, Suporn Ungkanont, Artit Aungchaisuksiri, Pantep Puavilai, Teeraya Jootar, Saengsuree |
author_sort | Niparuck, Pimjai |
collection | PubMed |
description | BACKGROUND: Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients. We therefore conducted a retrospective study of 42 consecutive patients with newly diagnosed and relapsed/refractory MM treated with thalidomide- based induction regimens followed by thalidomide maintenance therapy. RESULTS: Induction regimens with thalidomide and dexamethasone, and the oral combination of melphalan, prednisolone and thalidomide were administrated in 22 and 16 patients, respectively. The remaining 4 patients received other thalidomide- containing regimens. Twenty-nine patients received thalidomide as a salvage regimen. Twenty-three out of 26 patients achieving complete remission (CR) and very good partial remission (VGPR) received thalidomide maintenance. Of the 41 evaluable patients, median time of treatment was 21 months (3- 45 months), ORR was 92.7% with a 63.4% CR/VGPR. With a median follow up of 23 months, 3-year- PFS and 3-year-OS were 58.6 and 72.6%, respectively. Median time to progression was 42 months. While 3-year-PFS and 3-year-OS in non-transplant patients receiving thalidomide maintenance therapy were 67 and 80%, respectively. CONCLUSIONS: Prolonged thalidomide therapy enhanced survival rate and less frequently developed serious toxicity in non-transplant multiple myeloma patients. |
format | Text |
id | pubmed-2828404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28284042010-02-25 Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand Niparuck, Pimjai Sorakhunpipitkul, Ladda Atichartakarn, Vichai Chuncharunee, Suporn Ungkanont, Artit Aungchaisuksiri, Pantep Puavilai, Teeraya Jootar, Saengsuree J Hematol Oncol Letter to the Editor BACKGROUND: Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients. We therefore conducted a retrospective study of 42 consecutive patients with newly diagnosed and relapsed/refractory MM treated with thalidomide- based induction regimens followed by thalidomide maintenance therapy. RESULTS: Induction regimens with thalidomide and dexamethasone, and the oral combination of melphalan, prednisolone and thalidomide were administrated in 22 and 16 patients, respectively. The remaining 4 patients received other thalidomide- containing regimens. Twenty-nine patients received thalidomide as a salvage regimen. Twenty-three out of 26 patients achieving complete remission (CR) and very good partial remission (VGPR) received thalidomide maintenance. Of the 41 evaluable patients, median time of treatment was 21 months (3- 45 months), ORR was 92.7% with a 63.4% CR/VGPR. With a median follow up of 23 months, 3-year- PFS and 3-year-OS were 58.6 and 72.6%, respectively. Median time to progression was 42 months. While 3-year-PFS and 3-year-OS in non-transplant patients receiving thalidomide maintenance therapy were 67 and 80%, respectively. CONCLUSIONS: Prolonged thalidomide therapy enhanced survival rate and less frequently developed serious toxicity in non-transplant multiple myeloma patients. BioMed Central 2010-01-05 /pmc/articles/PMC2828404/ /pubmed/20051128 http://dx.doi.org/10.1186/1756-8722-3-1 Text en Copyright ©2010 Niparuck et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Letter to the Editor Niparuck, Pimjai Sorakhunpipitkul, Ladda Atichartakarn, Vichai Chuncharunee, Suporn Ungkanont, Artit Aungchaisuksiri, Pantep Puavilai, Teeraya Jootar, Saengsuree Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand |
title | Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand |
title_full | Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand |
title_fullStr | Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand |
title_full_unstemmed | Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand |
title_short | Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand |
title_sort | treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from thailand |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828404/ https://www.ncbi.nlm.nih.gov/pubmed/20051128 http://dx.doi.org/10.1186/1756-8722-3-1 |
work_keys_str_mv | AT niparuckpimjai treatmentoutcomeofthalidomidebasedregimensinnewlydiagnosedandrelapsedrefractorynontransplantmultiplemyelomapatientsasinglecenterexperiencefromthailand AT sorakhunpipitkulladda treatmentoutcomeofthalidomidebasedregimensinnewlydiagnosedandrelapsedrefractorynontransplantmultiplemyelomapatientsasinglecenterexperiencefromthailand AT atichartakarnvichai treatmentoutcomeofthalidomidebasedregimensinnewlydiagnosedandrelapsedrefractorynontransplantmultiplemyelomapatientsasinglecenterexperiencefromthailand AT chuncharuneesuporn treatmentoutcomeofthalidomidebasedregimensinnewlydiagnosedandrelapsedrefractorynontransplantmultiplemyelomapatientsasinglecenterexperiencefromthailand AT ungkanontartit treatmentoutcomeofthalidomidebasedregimensinnewlydiagnosedandrelapsedrefractorynontransplantmultiplemyelomapatientsasinglecenterexperiencefromthailand AT aungchaisuksiripantep treatmentoutcomeofthalidomidebasedregimensinnewlydiagnosedandrelapsedrefractorynontransplantmultiplemyelomapatientsasinglecenterexperiencefromthailand AT puavilaiteeraya treatmentoutcomeofthalidomidebasedregimensinnewlydiagnosedandrelapsedrefractorynontransplantmultiplemyelomapatientsasinglecenterexperiencefromthailand AT jootarsaengsuree treatmentoutcomeofthalidomidebasedregimensinnewlydiagnosedandrelapsedrefractorynontransplantmultiplemyelomapatientsasinglecenterexperiencefromthailand |